Denosumab in a pediatric kidney transplant recipient with late, resistant hypercalcemia secondary to Pneumocystis jirovecii pneumonia
Pediatric Nephrology · 2024
DOI: 10.1007/s00467-024-06288-7 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Nephrology, 2024. Verfasst von Felicity Beale und 4 weiteren Autor:innen. Beteiligte Einrichtung: Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Denosumab, Hypercalcemia, Kidney Transplantation, Pneumocystis carinii. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kidney transplant recipients (KTR) are at an increased risk of developing Pneumocystis jirovecii pneumonia (PCP), especially during the first year after transplantation. This is the first reported pediatric KTR, with chronic kidney disease (CKD) secondary to kidney dysplasia and vesicoureteral reflux, who developed refractory and symptomatic hypercalcemia 5 years after transplantation. The hypercalcemia was resistant to treatment with intravenous hyperhydration, furosemide, and a low-calcium diet. A respiratory tract infection due to PCP treated with trimethoprim-sulfamethoxazole did not improve calcium levels. Due to the hypercalcemic symptom burden for the patient, a single dose of subcutaneous denosumab was used to achieve sustained clinical and biochemical improvement, without any severe adverse events. This case highlights the potential use of denosumab as a treatment option in pediatric KTR with refractory hypercalcemia related to PCP. Further study of denosumab in young people with CKD or kidney transplants is needed before routine use can be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom.
- 4th Pediatric Department AUTH, "Papageorgiou" General Hospital, Thessaloniki, Greece.
- Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom. alex.lalayiannis@nhs.net.
ORCID-Profile: Alexander D Lalayiannis
Zitieren
APA
Beale, F., Gkiourtzis, N., Koneru, S., O'Brien, C., & Lalayiannis, A. D. (2024). Denosumab in a pediatric kidney transplant recipient with late, resistant hypercalcemia secondary to Pneumocystis jirovecii pneumonia. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06288-7
Vancouver
Beale F, Gkiourtzis N, Koneru S, O'Brien C, Lalayiannis AD. Denosumab in a pediatric kidney transplant recipient with late, resistant hypercalcemia secondary to Pneumocystis jirovecii pneumonia. Pediatric Nephrology. 2024. doi:10.1007/s00467-024-06288-7
BibTeX
@article{Beale2024,
author = {Beale, Felicity and Gkiourtzis, Nikolaos and Koneru, Sahiti and O'Brien, Catherine and Lalayiannis, Alexander D},
title = {Denosumab in a pediatric kidney transplant recipient with late, resistant hypercalcemia secondary to Pneumocystis jirovecii pneumonia},
journal = {Pediatric Nephrology},
year = {2024},
doi = {10.1007/s00467-024-06288-7}
}
EUVIMED